 AIM ImmunoTech Inc NYSE:AIM said it has a strong balance sheet that will fund operations and clinical development programs through 2023. In a statement reporting its financial results for 2021, the Florida-based company said it ended the year with cash and cash equivalents of 48.3 million as it advances its flagship drug candidate Ampligen rintatolimod to treat cancers, viral diseases and disorders of the immune system. 